Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究(IMPAACT 2017/MOCHA):一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究 The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Certara2025 年 3 月 20 日
How biosimulation and virtual trials can bust through clinical trial roadblocks Press Coverage How biosimulation and virtual trials can bust through clinical trial roadblocks Discover how using biosimulation for rare disease drug development can help overcome statistical and recruitment…Certara2025 年 3 月 14 日
MIDD in Japan – Implementations, challenges and opportunities Publication MIDD in Japan – Implementations, challenges and opportunities In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…Certara2025 年 3 月 12 日
Model-Informed Drug Development in the Age of AI On-Demand Webinar 人工智能时代的模型引导的药物开发 Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…Certara2025 年 3 月 10 日
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach Publication Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…Certara2025 年 3 月 4 日
Machine Learning for PK/PD Modeling in Drug Development Blog 药物开发中 PK/PD 建模的机器学习 Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…Certara2025 年 3 月 4 日
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement Publication The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…Certara2025 年 2 月 25 日
Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA) Fact Sheet 定量药理学在药物开发中的决策支持:基于模型的荟萃分析(MBMA) Whether you’re optimizing trial design or seeking strategic insights, Certara’s MBMA delivers the clarity and…Certara2025 年 2 月 19 日
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Video Certara Phoenix 平台 — 全球最值得信赖的药代动力学/药效学(PK/PD)分析与建模平台 Today’s drug candidates are more complex than ever. But with development decisions on the line,…Certara2025 年 2 月 12 日
Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease Poster 利用模拟结果为探索全人源抗 IL-6 抗体 TOUR006 治疗甲状腺眼病的 IIb 期试验确定剂量 Certara2025 年 2 月 7 日